As of November 6, 2026, Lantern Pharma Inc. is a publicly traded company (Nasdaq: LTRN); its largest reported holder is Thomas A. Satterfield, Jr., with 7.6% on Schedule 13G/A of July 23, 2026 (Schedule 13G/A, July 23, 2026).
Is this your company?
About to sign with, pay or invest in Lantern Pharma Inc.? See the free Snapshot first.
Free to see. No signup.
Is Lantern Pharma Inc. a real, registered company?
- Lantern Pharma Inc. files with the SEC under CIK 1763950 (its SEC filings).
- Its shares are listed under the ticker LTRN on Nasdaq (SEC company record).
- Incorporated in Texas; business address in Dallas, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Lantern Pharma Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Empery Asset Management, LP (filed 2026-08-04).
Who are Lantern Pharma Inc.'s owners and officers?
Lantern Pharma Inc.: incorporated in Texas; business address in Dallas, Texas; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-13).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-05-21)
- : Director (Form D, 2026-05-21)
- : Executive Officer (Form D, 2026-05-21)
- : Executive Officer (Form D, 2026-05-21)
- : Director (Form D, 2026-05-21)
- : Director (Form D, 2026-05-21)
- : Director (Form D, 2026-05-21)
- : Director (Form D, 2026-05-21)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-13 | Empery Asset Management, LP | 4.99% |
| Schedule 13G, 2026-08-04 | Empery Asset Management, LP | 9.99% |
| Schedule 13G/A, 2026-07-23 | Thomas A. Satterfield, Jr. | 7.6% |
| Schedule 13D/A, 2026-05-15 | Bios Equity Partners, LP | 4.48% |
| Schedule 13D/A, 2026-04-16 | Bios Equity Partners, LP | 7.4% |
| Schedule 13G, 2026-04-03 | Thomas A. Satterfield, Jr. | 5.1% |
| Schedule 13D/A, 2026-02-23 | Bios Equity Partners, LP | 8.58% |
Questions about who owns Lantern Pharma Inc.
Who owns Lantern Pharma Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Lantern Pharma Inc.: Thomas A. Satterfield, Jr. (7.6%, Schedule 13G/A, filed 2026-07-23).
When did Thomas A. Satterfield, Jr. buy into Lantern Pharma Inc.?
The filings give report dates, not purchase dates. The earliest filing from Thomas A. Satterfield, Jr. on this page is the Schedule 13G, filed 2026-04-03, reporting 5.1%; its latest, Schedule 13G/A filed 2026-07-23, reports 7.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Lantern Pharma Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Lantern Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lantern Pharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Lantern Pharma Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , LP, a 10% owner: 1,075,952 shares (8.4% of shares outstanding), held indirectly through By Bios Fund II QP, LP and 2 others, on a joint filing (Form 4, 2025-06-13).
- , a 10% owner: 1,075,952 shares (8.4% of shares outstanding), held indirectly through By Bios Fund II QP, LP and 2 others, on a joint filing (Form 4, 2025-06-13).
- Cavu Management, LP, a 10% owner: 1,075,952 shares (8.4% of shares outstanding), held indirectly through By Bios Fund II QP, LP and 2 others, on a joint filing (Form 4, 2025-06-13).
- BIOS Advisors GP, LLC, a 10% owner: 1,075,952 shares (8.4% of shares outstanding), held indirectly through By Bios Fund I, LP and 2 others, on a joint filing (Form 4, 2025-06-13).
- Cavu Advisors, LLC, a 10% owner: 1,075,952 shares (8.4% of shares outstanding), held indirectly through By Bios Fund II QP, LP and 2 others, on a joint filing (Form 4, 2025-06-13).
Shares outstanding: 12,784,146 as of 2026-08-10, from the company's latest SEC cover page.
How much has Lantern Pharma Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-05-21 | $0 | $0 |
Latest IPO step: Lantern Pharma Inc. filed to go public (S-1, 2026-06-12).
IPO filings: S-1, 2026-06-12; ticker LTRN on Nasdaq Capital Market.
Keep reading
More on Lantern Pharma Inc. and the records around it.
Lantern Pharma Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Thomas A. Satterfield, Jr. also filed stake reports on 8 other companies: Curis, Inc. (May 2026), enVVeno Medical Corporation (Nov 2025), OS Therapies Incorporated (Aug 2025)
- Empery Asset Management, LP also filed stake reports on 21 other companies: Dyadic International Inc. (Oct 2026), Femasys Inc. (Oct 2026), Clene Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/lantern-pharma